Health
Novavax Studies for Flu, Covid Vaccines on Hold Over Safety
- A vaccine study participant developed a serious nerve disorder
- Company and FDA investigating the single adverse event report
This article is for subscribers only.
Novavax Inc. shares fell 19% after US regulators placed a hold on the company’s experimental vaccines because a study volunteer developed a serious nerve disorder.
The pause applies to the company’s stand-alone influenza shots and the influenza and Covid combination vaccine, Novavax said in a statement. Chief Medical Officer Robert Walker said the company doesn’t believe causality has been established and it’s working with regulators to resolve the issue.